Literature DB >> 7089768

Lymphocytic infiltration of pleural mesothelioma and its significance for survival.

R A Leigh, I Webster.   

Abstract

Pleural mesothelioma is an uncommon but usually highly malignant tumour. A study has been made of 110 cases from the Mesothelioma Register of the National Centre for Occupational Health. Adequate information regarding survival was documented in 63 cases. In 5 of the latter there was insufficient tissue for accurate classification. Thirty-five patients were dead within 9 months of first presentation, and in 33 of these there was an insignificant or absent lymphoid reaction. Fifteen patients survived 18 months or more, and 10 of these had a significant lymphocytic infiltration in the original biopsies. In an intermediate group of 8 patients, who survived between 9 and 18 months, a variable lymphoid reaction occurred. We conclude that the presence of significant lymphoid infiltration indicates a better prognosis for longer survival in patients with pleural mesothelioma.

Entities:  

Mesh:

Year:  1982        PMID: 7089768

Source DB:  PubMed          Journal:  S Afr Med J


  15 in total

Review 1.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

2.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

4.  B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

Authors:  Aaron Scott Mansfield; Anja C Roden; Tobias Peikert; Yuri M Sheinin; Susan M Harrington; Christopher J Krco; Haidong Dong; Eugene D Kwon
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

Review 5.  Malignant pleural mesothelioma.

Authors:  Siva Raja; Sudish C Murthy; David P Mason
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

6.  Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.

Authors:  Kei Suzuki; Kyuichi Kadota; Camelia S Sima; Michel Sadelain; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-07-19       Impact factor: 6.968

Review 7.  Novel therapies in phase II and III trials for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  J Natl Compr Canc Netw       Date:  2012-01       Impact factor: 11.908

8.  Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.

Authors:  Assunta De Rienzo; William G Richards; Beow Y Yeap; Melissa H Coleman; Peter E Sugarbaker; Lucian R Chirieac; Yaoyu E Wang; John Quackenbush; Roderick V Jensen; Raphael Bueno
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

9.  Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.

Authors:  Swati Khanna; Anish Thomas; Daniel Abate-Daga; Jingli Zhang; Betsy Morrow; Seth M Steinberg; Augusto Orlandi; Patrizia Ferroni; Jeffrey Schlom; Fiorella Guadagni; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2016-08-17       Impact factor: 15.609

10.  Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.

Authors:  Edwin R Parra; Jie Zhai; Auriole Tamegnon; Nicolas Zhou; Renganayaki Krishna Pandurengan; Carmelia Barreto; Mei Jiang; David C Rice; Caitlin Creasy; Ara A Vaporciyan; Wayne L Hofstetter; Anne S Tsao; Ignacio I Wistuba; Boris Sepesi; Cara Haymaker
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.